Nurse Practitioner, Family · Las Vegas, NV
NPI
1811331226
Since 2013
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
5440 W Sahara Ave # 302
Las Vegas, NV, 89146
Phone (702) 633-0207
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
461 services
Medicare patients, 2024
167
Average age 70
Drug cost, 2024
$2.3M
2,119 prescriptions
Company payments, 2025
$4,165
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daisy Vo was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 170 times for 113 patients. In total Daisy Vo billed 461 services in 8 codes, and Medicare paid $21K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-08-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 170 | 113 | $10.99 | $1,868 |
| 99213 Office E&M - Established | Office | 136 | 102 | $50.68 | $6,892 |
| 99214 Office E&M - Established | Office | 97 | 59 | $81.10 | $7,867 |
| 99203 Office E&M - New | Office | 23 | 23 | $69.65 | $1,602 |
| 99204 Office E&M - New | Office | 17 | 17 | $112.77 | $1,917 |
By year: 2022 $25K for 376 services; 2023 $21K for 327 services; 2024 $21K for 461 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daisy Vo prescribed most often to Medicare patients was Ursodiol, with 268 prescriptions and refills. In total Daisy Vo wrote 2,119 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ursodiol Generic | 268 | 366 | 53 | $263K |
| Pantoprazole Sodium Generic | 176 | 252 | 79 | $720 |
| Omeprazole Generic | 109 | 134 | 38 | $647 |
| Spironolactone Generic | 106 | 156 | 43 | $802 |
| Furosemide Generic | 103 | 174 | 45 | $362 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 92 | 92 | 88 | $1,489 |
| Lactulose Generic | 90 | 116 | 42 | $1,480 |
| Famotidine Generic | 79 | 108 | 32 | $416 |
| Xifaxan Rifaximin | 67 | 67 | 15 | $215K |
| Azathioprine Generic | 67 | 131 | 16 | $953 |
| Tenofovir Disoproxil Fumarate Generic | 65 | 106 | 14 | $7,333 |
| Mycophenolate Mofetil Generic | 61 | 79 | 13 | $2,127 |
| Tacrolimus Generic | 51 | 89 | 12 | $4,834 |
| Clenpiq Sod Picosulf/Mag Ox/Citric Ac | 49 | 49 | 48 | $8,544 |
| Propranolol Hcl Generic | 44 | 84 | 19 | $340 |
Brand drugs: 471 claims; generic drugs: 1,648 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daisy Vo $4,165 ($4,165 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $1,946.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 30 | $1,946 |
| Gilead Sciences, Inc. GILD | 25 | $687 |
| Janssen Biotech, Inc. JNJ | 16 | $346 |
| Novo Nordisk Inc NVO | 4 | $166 |
| Madrigal Pharmaceuticals MDGL | 1 | $142 |
| Aimmune Therapeutics, Inc. | 2 | $140 |
| Intra-Sana Laboratories | 7 | $136 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 5 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 5 | $98.82 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $66.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.